Literature DB >> 23467067

The insulin-like growth factor-system in a patient with diffuse large B-cell non-Hodgkin's lymphoma and lactic acidosis.

Demelza Hoogwerf1, Jaap van Doorn, Eduard Maartense.   

Abstract

Lactic acidosis is a rare complication of haematological malignancies with a poor prognostic outcome and unclear aetiology. Possible mechanisms include high rate of glycolysis by cancer cells, in part due to over-expression of hexokinase II. The insulin-like growth factor (IGF)-system has an important role in normal as well as tumour cell growth. We present a case of a 79-year-old man with a diffuse large B-cell lymphoma and lactic acidosis. Initially, the patient was successfully treated according to the R-CHOP scheme. After recurrence of disease, the patient was treated according to a protocol of the Dutch-Belgian Haemato-Oncology Group (HOVON-85 study). Eleven months after completion of the last therapy, the patient still appeared to be in complete remission. Serum levels of IGFs, pro-IGF-IIE[68-88], IGF binding proteins (IGFBPs)-1 to -4, acid labile subunit (ALS), as well as ternary IGF-I-IGFBP-3-ALS complex formation, were determined in samples taken before, during and after treatment, respectively. Before treatment patient's serum concentration of the growth hormone-dependent parameters of the IGF-system and IGF-II were clearly reduced when compared with patient's values during remission of disease. On the other hand, during acidosis a relatively higher proportion of IGFs is present in binary complexes, instead of 150 kDa complexes, that may allow an increased access of IGFs to target cells including the malignant ones. Pretreatment serum levels of IGFBP-1 and -2 were elevated, decreased during therapy and normalized at remission. Especially IGFBP-2 seems a suitable marker for disease activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467067     DOI: 10.1258/acb.2012.012125

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  2 in total

1.  Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Authors:  Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-07-14       Impact factor: 12.531

2.  Complete heart block and persistent lactic acidosis as an initial presentation of non-hodgkin lymphoma in a critically ill newly diagnosed AIDS patient.

Authors:  Mohsin Ijaz; Hassan Tariq; Masooma Niazi; Dmitry Lvovsky
Journal:  Case Rep Crit Care       Date:  2014-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.